---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083084"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2023-07-21T23:59:59+00:00"
generated_at: "2026-06-13T04:57:03.719238+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald

## Summary
- ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.
- Commission of 3.0% of gross proceeds paid to Cantor; Company provides customary indemnification.
- Shares sold under existing effective shelf registration statement (File No. 333-254996).
- No obligation to sell; offering terminates upon full issuance or termination of agreement.

## SEC filing metadata
- accession: 0001104659-23-083084
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2023-07-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465923083084/0001104659-23-083084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465923083084/tm2321697d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083084
- JSON: https://secwatch.observer/filing/0001104659-23-083084.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083084.txt

## Key facts
- Material Agreements
  Hepion Pharmaceuticals, Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at up to $24,000,000 (effective 2023-07-21).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: up to $24,000,000
  - Effective: 2023-07-21
  source text: On July 21, 2023, Hepion Pharmaceuticals, Inc. (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. as sales agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $24,000,000 (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465923083084/0001104659-23-083084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.